U.S. Semiconductors Stock News

Some investors may be wondering if Par Pacific Holdings at around US$61.56 is still offering value, or if most of the opportunity is already priced in. The stock has had a mixed short term patch, with a 2.7% decline over 7 days and a flat 0.3% move over 30 days, but sits on returns of 71.9% year to date and 341.0% over the past year. Recent coverage has focused on Par Pacific Holdings as an energy name that has attracted attention after strong share price performance and increased interest...

Wondering if Axcelis Technologies at around US$133 per share still offers value, or if most of the upside may already be reflected in the price. The stock has posted returns of 17.8% over 7 days, 57.8% over 30 days, 54.7% year to date and 195.3% over 1 year. This naturally raises questions about potential growth and shifts in perceived risk. These sharp moves sit against a backdrop of ongoing investor interest in semiconductor equipment providers and how they fit into longer term chip...

In mid-April 2026, NetApp announced an expanded four-year Enterprise Agreement with Google Cloud to deploy its AFF, StorageGRID, and Trident storage solutions within Google Distributed Cloud air-gapped, a sovereign, fully disconnected cloud platform delivered by World Wide Technology to support sensitive, regulated workloads. This collaboration positions NetApp at the center of secure, AI-enabled private cloud deployments, enabling organizations to run Gemini-powered generative AI...

Peoples Bancorp of North Carolina (PEBK) opened 2026 with Q1 revenue of US$21.0 million and basic EPS of US$0.83, supported by trailing twelve month revenue of US$89.9 million and EPS of about US$3.75 as profitability strengthened over the past year. The bank has seen trailing EPS move from about US$3.08 to roughly US$3.75 over the last six reported quarters, while net income over the same trailing period reached US$19.9 million. This sets up the latest result against an earnings profile that...

AMC Robotics (AMCI) has just wrapped up FY 2025 with Q4 revenue of US$1.3 million and a basic EPS loss of US$0.52, while trailing twelve month figures show revenue of US$6.0 million and a basic EPS loss of US$1.36 alongside a reported 41.4% revenue decline over the year. Over the past few reported periods, quarterly revenue has ranged from US$1.3 million to US$3.2 million and basic EPS has swung between a profit of US$0.15 and a loss of US$0.52, underscoring how volatile the earnings line has...

On April 13, 2026, CG Oncology, Inc. appointed Jim DeTore as Chief Financial Officer after he had served as Interim Principal Financial and Accounting Officer since November 2025 and previously held senior finance roles at several biotechnology companies, including Neurogastrx, Proteostasis Therapeutics, and Bluebird Bio. This appointment adds long-tenured biotech financial leadership at a time when CG Oncology’s oncolytic immunotherapy program for bladder cancer is attracting increased...

Ciena (NYSE:CIEN) is partnering with Lightstorm to upgrade the Japan, Guam, Australia submarine cable system with advanced optical networking technology. The project focuses on the Tokyo to Sydney route, where capacity is set to be quadrupled to support heavier data traffic. The upgraded system is intended to serve cloud and AI workloads that rely on high performance international connectivity. Ciena comes into this agreement with Lightstorm after a period of very strong share price...

Critical Metals Corp. recently entered into a securities purchase agreement to issue 5,999,998 ordinary shares at US$10.00 each, raising US$59,999,980 through a Regulation D private placement that was expected to close on or about April 22, 2026. This sizeable capital injection via a private placement can influence how investors think about Critical Metals’ funding capacity, project pipeline, and future dilution risk. We’ll now examine how this nearly US$60 million private placement shapes...

IDEAYA Biosciences (NasdaqGS:IDYA) has entered a clinical collaboration with AstraZeneca to study IDE849, a DLL3 TOP1 antibody drug conjugate. The program will evaluate IDE849 in combination with Imfinzi in extensive stage small cell lung cancer and other DLL3 upregulated tumors. For readers tracking IDEAYA mainly through its uveal melanoma drug darovasertib, this collaboration with AstraZeneca broadens the story. The company, trading at $31.83, has delivered a 70.9% return over the past...

Wintrust Financial (WTFC) opened 2026 with Q1 revenue of US$682.4 million and basic EPS of US$3.26, while trailing twelve month revenue stood at US$2.7 billion and EPS at US$12.10. This gives investors a clear snapshot of both the latest quarter and the broader earnings run rate. Over the past year, revenue has moved from US$2.3 billion to US$2.7 billion and trailing EPS has shifted from US$10.47 to US$12.10, setting the backdrop for how the market may read this earnings print. With a...

If you are wondering whether Calix at around US$49.58 still offers value or is starting to look stretched, the key is to look closely at what you are paying for each dollar of its future potential. The share price performance is mixed, with a 1.6% gain over the last 7 days, a 1.5% decline over 30 days, a 7.5% decline year to date, and a 31.8% return over the past year. These shifts can change how the market views both risk and opportunity. Investors have been reacting to ongoing industry...

With inflation, energy shocks and bond yields all in focus, many investors are looking for companies that are not only surviving the noise but also backed by strong fundamentals. A solid balance sheet and high return on equity can help show which businesses are using capital efficiently while keeping financial risk in check. That is exactly what the Solid Balance Sheet and Fundamentals screener is built to highlight. In this article, you will see three stocks filtered by that approach, along...

Progress Software (PRGS) shares are in focus after the company announced a relocation and expansion of its Bengaluru office, highlighting India’s growing role in its AI work and customer facing operations. See our latest analysis for Progress Software. The Bengaluru expansion comes at a time when Progress Software’s share price return has weakened, with a 29.6% decline over 90 days and a 46.9% drop in 1 year total shareholder return. This is despite a 6.7% 7 day share price rebound that hints...

Mueller Industries (MLI) opened Q1 2026 with revenue of US$1.2b and basic EPS of US$2.19, supported by net income of US$239.0m. This sets a clear marker for how the year is starting to shape up. Over the past year, the company has seen trailing twelve month revenue move from US$3.8b to US$4.4b, with basic EPS over that period rising from US$5.43 to US$7.76. This gives investors a fuller picture of the earnings engine behind the latest quarterly print. With a trailing net margin sitting...

Q1 2026 earnings snapshot Danaher (DHR) opened 2026 with Q1 revenue of US$5.9b and basic EPS of US$1.45, setting the tone for how investors will judge the rest of the year against a share price around US$194.54. Over the past six reported quarters, revenue has ranged from US$5.7b to US$6.8b while quarterly basic EPS has moved between roughly US$0.77 and US$1.67, giving you a clear view of how top line scale and per share earnings have tracked together into the latest print. With trailing 12...

Wondering whether Intuit at around US$404.85 is starting to look attractively priced, or if the recent share moves are just noise in your watchlist? Over the past week the stock has moved 10.4%, set against a 30 day return of an 11.1% decline and a year to date return of a 35.7% decline, which puts the 1 year return at a 30.1% decline and the 3 and 5 year returns close to flat. Recent headlines have focused on Intuit's role as a key software provider and on how market sentiment around large...

If you are wondering whether Alibaba Group Holding's current share price still reflects good value, the recent mix of returns gives you plenty to think about. The stock last closed at US$135.38, with returns of 3.1% over 7 days, 10.6% over 30 days, 18.8% over 1 year, a 71.8% gain over 3 years, a 39.6% decline over 5 years, and a 13.1% decline year to date. These moves have come as investors continue to weigh broader sentiment around Chinese technology companies and any regulatory signals...

Sidus Space, Inc. recently completed a US$58.52 million registered direct follow-on equity offering and, earlier in April 2026, announced an expanded agreement with Lonestar Data Holdings to build and deliver an additional StarVault orbital data storage payload for launch no earlier than fall 2026. The expanded Lonestar collaboration positions Sidus Space more deeply in emerging space-based sovereign data storage infrastructure, highlighting its role in supporting commercial, government, and...

If you are wondering whether Semtech's share price still reflects good value after a strong run, it helps to step back and look at what the current valuation is really pricing in. The stock last closed at US$103.48, with returns of 14.8% over 7 days, 40.6% over 30 days, 37.5% year to date and 319.1% over the past year. Any view on value now needs to factor in that kind of move. Recent news coverage has focused on Semtech's position within the broader semiconductor space and how investors are...

Rush Street Interactive overview Rush Street Interactive (RSI) has been catching investor attention after a strong run in its shares over the past year, prompting a closer look at how its current business metrics stack up. See our latest analysis for Rush Street Interactive. The recent momentum in Rush Street Interactive has been strong, with a 12.27% 1 month share price return and a 25.76% 3 month share price return contributing to a very large 3 year total shareholder return. This suggests...

At the American College of Cardiology 2026 Annual Scientific Sessions, iRhythm Technologies reported favorable analysis results for its Zio cardiac monitoring device and introduced iRhythm Academy, an education platform for healthcare professionals in cardiac monitoring. The new data highlighting clinically actionable arrhythmias in patients with chronic kidney disease, diabetes, and severe obesity could reinforce Zio’s relevance in managing high‑risk, comorbid populations. We’ll now explore...

If you are wondering whether Caris Life Sciences at around US$20.83 offers good value, the key is understanding how the current price lines up against its fundamentals. The stock has recently been active, with a 3.2% return over the last 7 days and 13.1% over the last 30 days, but a 22.8% decline year to date, which can change how investors think about both opportunity and risk. Recent news coverage has focused on Caris Life Sciences as part of the broader interest in healthcare and biotech...

Antero Resources (AR) has drawn fresh attention after recent trading left the stock with a 1 day return of 1.6% and a past month return of 13.8%, in contrast with an 8.5% gain over the past 3 months. See our latest analysis for Antero Resources. At a share price of $37.16, Antero Resources has seen shorter term share price momentum cool with a 30 day share price return of a 13.8% decline. Longer term total shareholder returns over 1, 3 and 5 years, at 13.2%, 68.1% and a very large 276.1%...

Herbalife Ltd. recently completed an $800 million fixed-income offering of 7.750% secured senior notes due 2033, issued at 100% of principal under Regulation S and Rule 144A. This substantial, guaranteed bond financing reshapes Herbalife’s capital structure and offers fresh insight into its approach to liquidity, refinancing needs, and funding future initiatives. Next, we’ll explore how issuing $800 million in secured senior notes could influence Herbalife’s investment narrative and future...